Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Daiichi Sankyo
US Department of Justice
Cipla
Teva
Medtronic

Generated: August 25, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,421,194

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,421,194
Title:Lung targeting dual drug delivery system
Abstract: The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.
Inventor(s): Prud\'homme; Robert K. (Lawrenceville, NJ), Sinko; Patrick J. (Annandale, NJ), Stone; Howard A. (Princeton, NJ), Pinkerton; Nathalie M. (Ottawa Hills, OH), Shi; Lei (Shanghai, CN), Wan; Jiandi (Lawrenceville, NJ), Ibrahim; Sherif (Old Bridge, NJ), Gao; Dayuan (East Brunswick, NJ)
Assignee: Rutgers, The State University of New Jersey (New Brunswick, NJ) The Trustees of Princeton University (Princeton, NJ)
Application Number:13/080,371
Patent Claims:1. A delivery system comprising a gel microparticle, a plurality of nanoparticles associated with the gel microparticle, and one or more hydrophobic drugs associated with at least one of the nanoparticles, wherein the gel microparticle includes aqueous soluble polymers or copolymers that are gelled by a crosslinking reaction selected from the group consisting of free radical polymerization, mannich reactions, hydrophobic association, metal ion mediated complexation, amide formation reactions, ester formation reactions, and azide alkyne Huisgen cycloaddition, and the nanoparticles include PEG protective coatings.

2. The delivery system of claim 1 further comprising at least one of one or more targeting agents associated with at least one of the nanoparticles or one or more chemopotentiator associated with at least one of the nanoparticles.

3. The delivery system of claim 1, wherein the gel microparticles include polymers and degradable linkages between individual ones of the polymers.

4. The delivery system of claim 1, wherein the gel microparticles have a size of 1-60 .mu.m.

5. The delivery system of claim 1, wherein the gel microparticles have a size selected from the group consisting of 6-10 .mu.m and 50-60 .mu.m.

6. The delivery system of claim 1, wherein the shear modulus of the gel microparticle is from 4 Pa to 200,000 Pa.

7. The delivery system of claim 1, wherein the gel microparticle includes gelled polymers or copolymers selected from at least one of poly(2-hydroxyethyl methacrylate), polyphosphate, polyethylene glycol, PEG, or copolymers thereof, dextran, polyvinyl pyrrolidone or co-polymers thereof, or polyacrylic acid or copolymers thereof.

8. The delivery system of claim 1, wherein the gel microparticle includes gelled polymers or copolymers selected from at least one of polyethylene glycol, PEG, having a molecular weight from 200 to 200,000 g/mole, dextran having a molecular weight from 200 to 100,000 g/mole, polyvinyl pyrrolidone or copolymers thereof having a molecular weight from 200 to 100,000 g/mole, or polylactic acid-polyethylene glycol-polylactic acid, PLA-PEG-PLA, polymers.

9. The delivery system claim 1, wherein the one or more hydrophobic drugs includes a substance selected from the group consisting of an asthma therapeutic agent, a chronic obstructive pulmonary disease therapeutic agent, a tuberculosis therapeutic agent, a cancer therapeutic agent, a non-small cell lung cancer therapeutic agent, signal transduction inhibitors, cytotoxic agents, cell cycle inhibitors, cell cycle control inhibitors, checkpoint inhibitors that interfere with the normal function of cell cycle checkpoints, checkpoint inhibitors that interfere with the normal function of cell cycle S/G2 checkpoint, checkpoint inhibitors that interfere with the normal function of cell cycle G2/M checkpoint, checkpoint inhibitors that interfere with the normal function of cell cycle G1/S checkpoint, topoisomerase inhibitors, camptothecins, enzymes necessary for DNA replication, enzymes necessary for DNA transcription, receptor tyrosine kinase inhibitors, apoptosis inducing agents, antimetabolites, gemcitabine, hydroxyurea, telomerase inhibitors, cyclin-dependent kinase inhibitors, cytoskeletal proteins, transcription factors, tumor suppresser genes, DNA damaging agents, DNA repair inhibitors, anti-angiogenic agents, mitochondrial poisons, carboplatin, cisplatin, cyclophosphamide, doxorubicin, daunorubicin, epirubicin, mitomycin C, mitoxantrone, 5-fluorouracil (5-FU), FUDR, methotrexate, topoisomerase I inhibitors, irinotecan, topotecan, S/G2 checkpoint inhibitors, bleomycin, docetaxel, etoposide, paclitaxel, vinblastine, vincristine, vindesine, vinorelbine, genistein, trastuzumab, ZD1839, apoptosis-inducing agents, a TB therapeutic agent, ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, aminoglycosides, amikacin (AMK), kanamycin (KM), polypeptides, capreomycin, viomycin, enviomycin, fluoroquinolones, ciprofloxacin (CIP), levofloxacin, moxifloxacin (MXF), thioamides, ethionamide, prothionamide, cycloserine, p-aminosalicylic acid (PAS or P), rifabutin, macrolides, clarithromycin (CLR), linezolid (LZD), thioacetazone (T), thioridazine, arginine, vitamin D, R207910, SQ641, a COPD therapeutic agent, short-acting selective beta.sub.2-adrenoceptor agonists, adrenergic agonists, anticholinergic medications and long-acting .beta..sub.2-agonists, or a pharmaceutically acceptable salt of one of the foregoing.

10. The delivery system of claim 1 further comprising a pharmaceutically acceptable carrier.

11. A method of treating a condition comprising administering a delivery system to a patient in need thereof, the delivery system including a gel microparticle, a plurality of nanoparticles associated with the gel microparticle, and one or more hydrophobic drugs associated with at least one of the nanoparticles, wherein the gel microparticle includes aqueous soluble polymers or copolymers that are gelled by a crosslinking reaction selected from the group consisting of free radical polymerization, mannich reactions, hydrophobic association, metal ion mediated complexation, amide formation reactions, ester formation reactions, and azide alkyne Huisgen cycloaddition, and the nanoparticles include PEG protective coatings.

12. The method of claim 11, wherein the step of administering includes intravenous injection.

13. The method of claim 11, wherein the step of administering includes intra-arterial injection.

14. The method of claim 11, wherein the delivery system further includes at least one of one or more targeting agents associated with the nanoparticles or one or more chemopotentiators associated with the nanoparticles.

15. The method of claim 11, wherein the gel microparticles include polymers and degradable linkages between individual ones of the polymers.

16. The method of claim 11, wherein the gel microparticles have a size of 1-60 .mu.m.

17. The method of claim 11, wherein the gel microparticles have a size selected from the group consisting of 6-10 .mu.m and 50-60 .mu.m.

18. The method of claim 11, wherein the one or more hydrophobic drugs includes a substance selected from the group consisting of an asthma therapeutic agent, a chronic obstructive pulmonary disease therapeutic agent, a tuberculosis therapeutic agent, a cancer therapeutic agent, a non-small cell lung cancer therapeutic agent, signal transduction inhibitors, cytotoxic agents, cell cycle inhibitors, cell cycle control inhibitors, checkpoint inhibitors that interfere with the normal function of cell cycle checkpoints, checkpoint inhibitors that interfere with the normal function of cell cycle S/G2 checkpoint, checkpoint inhibitors that interfere with the normal function of cell cycle G2/M checkpoint, checkpoint inhibitors that interfere with the normal function of cell cycle G1/S checkpoint, topoisomerase inhibitors, camptothecins, enzymes necessary for DNA replication, enzymes necessary for DNA transcription, receptor tyrosine kinase inhibitors, apoptosis inducing agents, antimetabolites, gemcitabine, hydroxyurea, telomerase inhibitors, cyclin-dependent kinase inhibitors, cytoskeletal proteins, transcription factors, tumor suppresser genes, DNA damaging agents, DNA repair inhibitors, anti-angiogenic agents, mitochondrial poisons, carboplatin, cisplatin, cyclophosphamide, doxorubicin, daunorubicin, epirubicin, mitomycin C, mitoxantrone, 5-fluorouracil (5-FU), FUDR, methotrexate, topoisomerase I inhibitors, irinotecan, topotecan, S/G2 checkpoint inhibitors, G2/M checkpoint inhibitors, bleomycin, docetaxel, etoposide, paclitaxel, vinblastine, vincristine, vindesine, vinorelbine, G1/early-S checkpoint inhibitors, genistein, trastuzumab, ZD1839, apoptosis-inducing agents, a TB therapeutic agent, ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, aminoglycosides, amikacin (AMK), kanamycin (KM), polypeptides, capreomycin, viomycin, enviomycin, fluoroquinolones, ciprofloxacin (CIP), levofloxacin, moxifloxacin (MXF), thioamides, ethionamide, prothionamide, cycloserine, p-aminosalicylic acid (PAS or P), rifabutin, macrolides, clarithromycin (CLR), linezolid (LZD), thioacetazone (T), thioridazine, arginine, vitamin D, R207910, SQ641, a COPD therapeutic agent, short-acting, selective beta.sub.2-adrenoceptor agonists, adrenergic agonists, anticholinergic medications and long-acting .beta..sub.2-agonists, or a pharmaceutically acceptable salt of one of the foregoing.

19. The method of claim 11, wherein the delivery system further includes a pharmaceutically acceptable carrier.

20. The delivery system of claim 1, wherein the one or more hydrophobic drugs include at least one hydrophobic drug selected from camptothecin, gemcitabine, carboplatin, cisplatin, doxorubicin, daunorubicin, topotecan, bleomycin, docetaxel, or paclitaxel.

21. The delivery system of claim 1, wherein the one or more hydrophobic drugs include at least one hydrophobic drug selected from ethambutol, isoniazid, pyrazinamide, rifampicin, or streptomycin.

22. The delivery system of claim 1, wherein the one or more hydrophobic drugs include camptothecin.

23. The delivery system of claim 1, wherein the one or more hydrophobic drugs include rifampicin.

24. The delivery system of claim 1, wherein the aqueous soluble polymers or copolymers include PEG polymers having a molecular weight of 200 to 200,000 g/mole.

25. The delivery system of claim 1, wherein the aqueous soluble polymers or copolymers are PEG polymers having a molecular weight of 200 to 200,000 g/mole and the one or more hydrophobic drugs include camptothecin.

26. The delivery system of claim 1, wherein the aqueous soluble polymers or copolymers are PEG polymers having a molecular weight of 200 to 200,000 g/mole and the one or more drugs include rifampicin.

27. The method of claim 11, wherein the one or more hydrophobic drugs include at least one hydrophobic drug selected from camptothecin, gemcitabine, carboplatin, cisplatin, doxorubicin, daunorubicin, topotecan, bleomycin, docetaxel, or paclitaxel.

28. The method of claim 11, wherein the one or more hydrophobic drugs include at least one hydrophobic drug selected from ethambutol, isoniazid, pyrazinamide, rifampicin, or streptomycin.

29. The method of claim 11, wherein the one or more hydrophobic drugs include camptothecin.

30. The method of claim 11, wherein the one or more hydrophobic drugs include rifampicin.

31. The method of claim 11, wherein the aqueous soluble polymers or copolymers include PEG polymers having a molecular weight of 200 to 200,000 g/mole.

32. The method of claim 11, wherein the aqueous soluble polymers or copolymers are PEG polymers having a molecular weight of 200 to 200,000 g/mole and the one or more hydrophobic drugs include camptothecin.

33. The method of claim 11, wherein the aqueous soluble polymers or copolymers are PEG polymers having a molecular weight of 200 to 200,000 g/mole and the one or more hydrophobic drugs include rifampicin.

Details for Patent 9,421,194

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Rutgers, The State University of New Jersey (New Brunswick, NJ) The Trustees of Princeton University (Princeton, NJ) 2030-04-05 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Johnson and Johnson
Citi
Federal Trade Commission
Merck
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.